Dr Suad Lateef Ibrahim Al-Mossawi

Electrolyte disturbances are common in ill patients. Several conditions in the intensive care unit (ICU) might be responsible for developing electrolyte disorders, and medications may also contribute to these disturbances. The current study aimed to determine the frequency of electrolyte disturbances and assess the pattern of electrolyte imbalance in hospitalized patients, determining the possible effects of these electrolyte disorders. This cross-sectional study included patients admitted to the intensive care unit, respiratory care unit (RCU), and coronary care unit (CCU) at the Al-Sadar teaching hospital, Najaf, Iraq, from November 2020 to April 2021. The study collected data from two hundred patients regarding demographics, categories of ICUs at admission, comorbidities, and laboratory values at admission. Also, electrolyte levels at ICU admission and during hospitalization were collected from the medical database record. In addition, the patient's age, sex, fasting blood sugar (FBS), body mass index (BMI), B.urea, and creatinine were matched. Na+, K+, ionized Ca++, and Cl serum levels were significantly different during hospitalization. Comorbidities with predominant hypokalemia were found in 80.5%, hypochloremia in 73%, hypocalcaemia in 72%, and hyponatremia in 56.7% of hospitalized patients. Studying the effect of co-morbidities indicated a higher percentage (44%) of admitted patients with ischemic heart diseases, 38 (19%) with digestive diseases, 21 (10.5%) with orthopedic surgery in an emergency, 14 (7%) with pneumonia and lung diseases, 12 (6%) with diabetics, 18 (9%) with sepsis, and 9(4.5%) with seizure. Hospitalized patients may be at higher risk of developing combined electrolytes disorder associated with decreased serum levels of K+, Na+, Ca++, and Cl- . Thus, clinicians are recommended to observe electrolyte changes and correct them as they seem to negatively impact the outcome and prognosis

Statins inhibit the synthesis of mevalonate, a precursor isoprenoid molecule to geranylgeraniol that is necessary for the post‑translational modification of several small GTPase oncogenes. Despite numerous preclinical studies suggesting that statins can be effective anticancer agents, prospective clinical trials have failed to demonstrate any clinical benefit in patients with cancer. We previously demonstrated that geranylgeraniol suppresses the activity of statins in cell culture studies, and that pitavastatin can cause regression of ovarian cancer xenografts in mice if the animals' diet is modified to avoid the inclusion of geranylgeraniol. Dietary sources of geranylgeraniol may consequently limit the activity of statins in cancer clinical trials. The present study tested several foods to identify those that affected the cytotoxic activity of pitavastatin towards ovarian cancer cells. Solvent extracts of several foods were tested for their ability to suppress the effects of pitavastatin in cell growth assays. The results revealed that pitavastatin induced cell death in ovarian cancer cells (IC50=5.2 µM) and this was blocked by geranylgeraniol whereas other products of the mevalonate pathway (coenzyme Q, dolichol or cholesterol) had no effect on the activity of pitavastatin in cell growth assays. Solvent extracts from several foods, especially oils (apart from rapeseed), also blocked the cytotoxic activity of pitavastatin. Several extracts from a range of fruit, vegetables and carbohydrate‑rich foods also did not block the activity of pitavastatin. However, extracts from beans, lettuce, oats, eggs and various nuts reduced the activity of pitavastatin. These data identified foods that patients could eat to potentially improve the outcome of clinical trials of pitavastatin in cancer.